$64.04
-5.20 (-7.51%)
Performance
1D
—
1W
-7.36%
1M
-2.65%
3M
-29.46%
6M
-49.03%
1Y
-13.69%
YTD
-36.31%
Open$68.28
Previous Close$69.24
Day High$68.77
Day Low$63.44
52W High$151.02
52W Low$53.54
Volume—
Avg Volume1.89M
Market Cap3.38B
P/E Ratio—
EPS$-4.30
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$76.26
Below
SMA 200
$100.07
Below
RSI (14)
69.6
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
18 analysts
Price Target
-60.1% upside
Current
$64.04
$64.04
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |